



either

R² denotes a hydrogen atom,

or

R¹ denotes a 4-chloro substituent, and

R² denotes a 2-chloro substituent,

or a medically acceptable salt or hydrate thereof.

14. (New) The substituted benzylthiazolidine-2,4-dione derivative or the medicinally acceptable salt or hydrate thereof of Claim 13, wherein R¹ denotes a 4-chloro, 3-trifluoromethyl, or 4-ethoxy substituent, and R² denotes a hydrogen atom.

15. (New) The substituted benzylthiazolidine-2,4-dione derivative of Claim 13, which is N-[(3-trifluoromethoxyphenyl)methyl]-5-[(2,4-dioxothiazolidin-5-yl)methyl]-2-methoxybenzamide, or a medically acceptable salt or hydrate thereof.


16. (New) The substituted benzylthiazolidine-2,4-dione derivative of Claim 13, which is N-[(4-ethoxyphenyl)methyl]-5-[(2,4-dioxothiazolidin-5-yl)methyl]-2-methoxybenzamide, or a medically acceptable salt or hydrate thereof.

17. (New) The substituted benzylthiazolidine-2,4-dione derivative of Claim 13, which is N-[(4-chlorophenyl)methyl]-5-[(2,4-dioxothiazolidin-5-yl)methyl]-2-methoxybenzamide, or a medicinally acceptable salt or hydrate thereof.

18. (New) The substituted benzylthiazolidine-2,4-dione derivative of Claim 13, which is N-[(2,4-dichlorophenyl)-methyl]-5-[(2,4-dioxothiazolidin-5-yl)methyl]-2-methoxybenzamide, or a medicinally acceptable salt or hydrate thereof.

19. (New) A tablet, capsule, granule, powder, inhalant, syrup, injectable composition, or suppository, comprising the substituted benzylthiazolidine-2,4-dione derivative or the medicinally acceptable salt or hydrate thereof of Claim 13.

20. (New) A tablet, capsule, granule, powder, inhalant, syrup, injectable composition, or suppository, comprising the substituted benzylthiazolidine-2,4-dione derivative or the medicinally acceptable salt or hydrate thereof of Claim 14.



21. (New) A tablet, capsule, granule, powder, inhalant, syrup, injectable composition, or suppository, comprising the substituted benzylthiazolidine-2,4-dione derivative or the medicinally acceptable salt or hydrate thereof of Claim 15.

22. (New) A tablet, capsule, granule, powder, inhalant, syrup, injectable composition, or suppository, comprising the substituted benzylthiazolidine-2,4-dione derivative or the medicinally acceptable salt or hydrate thereof of Claim 16.

23. (New) A tablet, capsule, granule, powder, inhalant, syrup, injectable composition, or suppository, comprising the substituted benzylthiazolidine-2,4-dione derivative or the medicinally acceptable salt or hydrate thereof of Claim 17.

24. (New) A tablet, capsule, granule, powder, inhalant, syrup, injectable composition, or suppository, comprising the substituted benzylthiazolidine-2,4-dione derivative or the medicinally acceptable salt or hydrate thereof of Claim 18.

25. (New) A method of reducing blood glucose, comprising administering an effective amount of the substituted benzylthiazolidine-2,4-dione derivative or the medicinally acceptable salt or hydrate thereof of Claim 13 to a subject in need thereof.

26. (New) A method of treating hyperlipidemia, comprising administering an effective amount of the substituted benzylthiazolidine-2,4-dione derivative or the medicinally acceptable salt or hydrate thereof of Claim 13 to a subject in need thereof.

27. (New) A method of reducing blood glucose, comprising administering an effective amount of the substituted benzylthiazolidine-2,4-dione derivative or the medicinally acceptable salt or hydrate thereof of Claim 14 to a subject in need thereof.

28. (New) A method of treating hyperlipidemia, comprising administering an effective amount of the substituted benzylthiazolidine-2,4-dione derivative or the medicinally acceptable salt or hydrate thereof of Claim 14 to a subject in need thereof.

29. (New) A method of reducing blood glucose, comprising administering an effective amount of the substituted benzylthiazolidine-2,4-dione derivative or the medicinally acceptable salt or hydrate thereof of Claim 15 to a subject in need thereof.

30. (New) A method of treating hyperlipidemia, comprising administering an effective amount of the substituted benzylthiazolidine-2,4-dione derivative or the medicinally acceptable salt or hydrate thereof of Claim 15 to a subject in need thereof.

31. (New) A method of reducing blood glucose, comprising administering an effective amount of the substituted benzylthiazolidine-2,4-dione derivative or the medicinally acceptable salt or hydrate thereof of Claim 16 to a subject in need thereof.

32. (New) A method of treating hyperlipidemia, comprising administering an effective amount of the substituted benzylthiazolidine-2,4-dione derivative or the medicinally acceptable salt or hydrate thereof of Claim 16 to a subject in need thereof.

33. (New) A method of reducing blood glucose, comprising administering an effective amount of the substituted benzylthiazolidine-2,4-dione derivative or the medicinally acceptable salt or hydrate thereof of Claim 17 to a subject in need thereof.

34. (New) A method of treating hyperlipidemia, comprising administering an effective amount of the substituted benzylthiazolidine-2,4-dione derivative or the medicinally acceptable salt or hydrate thereof of Claim 17 to a subject in need thereof.

A₁
Conf
35. (New) A method of reducing blood glucose, comprising administering an effective amount of the substituted benzylthiazolidine-2,4-dione derivative or the medicinally acceptable salt or hydrate thereof of Claim 18 to a subject in need thereof.

36. (New) A method of treating hyperlipidemia, comprising administering an effective amount of the substituted benzylthiazolidine-2,4-dione derivative or the medicinally acceptable salt or hydrate thereof of Claim 18 to a subject in need thereof.--

SUPPORT FOR THE AMENDMENTS

Newly added Claims 13-36 are supported by the specification at pages 4-11, especially the Examples, and by original Claims 1-12. No new matter is believed to have been added to this application by these amendments.

REMARKS

Claims 13-36 are now pending. Favorable reconsideration is respectfully requested.

The rejection of the claims under 35 U.S.C. §103(a) over Maeda et al., EP 0 846 693, hereinafter referred to as "Maeda '693", or Maeda et al., JP 08-333355, hereinafter referred to as "Maeda '355", is respectfully traversed. These references fail to suggest the claimed compounds.